Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Valerio De Stefano and Alessandro Vannucchi.
Valerio De Stefano
Connection Strength
2.116
Alessandro Vannucchi
  1. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
    View in: PubMed
    Score: 0.232
  2. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia. 2020 10; 34(10):2813-2814.
    View in: PubMed
    Score: 0.225
  3. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey. Leukemia. 2020 10; 34(10):2805-2808.
    View in: PubMed
    Score: 0.223
  4. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera. Blood Cancer J. 2018 11 26; 8(12):124.
    View in: PubMed
    Score: 0.199
  5. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018 11 12; 8(11):112.
    View in: PubMed
    Score: 0.199
  6. Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms. Blood Cancer J. 2018 11 07; 8(11):103.
    View in: PubMed
    Score: 0.198
  7. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018 02 28; 8(3):25.
    View in: PubMed
    Score: 0.189
  8. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
    View in: PubMed
    Score: 0.188
  9. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007 Aug 01; 110(3):840-6.
    View in: PubMed
    Score: 0.089
  10. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021 12 01; 96(12):1580-1586.
    View in: PubMed
    Score: 0.060
  11. Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
    View in: PubMed
    Score: 0.059
  12. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
    View in: PubMed
    Score: 0.058
  13. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 08; 8(9):4089-4092.
    View in: PubMed
    Score: 0.052
  14. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 09 21; 8(10):89.
    View in: PubMed
    Score: 0.049
  15. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018 06; 69:100-102.
    View in: PubMed
    Score: 0.048
  16. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 09; 103(9):e392-e394.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.